These results extend previous knowledge on the non-immuno-related anti-tumor activities of epigenetic inhibitors, such as reactivation of tumor suppressor genes by demethylating agents [47], promotion of cell death and suppression of angiogenesis by HDAC inhibitors [48], inhibition of proto-oncogenes MYC and BCL2 by BET inhibitors [49] and downregulation of DNA repair genes by EZH2 inhibitors [50]. Here, MYC is linked to neoplasm.